Radicle Science, an AI-driven healthtech B-corp, announced the launch of its Radicle Proof Engine™, history’s first Proof-as-a-Service solution that enables non-pharmaceutical health and wellness products to clinically prove their true effects beyond placebo. Until now, non-pharmaceuticals have been unable to generate scientifically validated proof of their effectiveness due to a lack of easy or affordable access to clinical trials.
Traditional trials, primarily serving patented pharmaceutical drugs, have simply been too expensive and slow for these unpatentable natural health products and dietary supplements products.
Also Read: Synack Expands Security Platform with Adversarial API Pentesting
The Radicle Proof Engine™ allows non-pharmaceuticals to generate first-of-its kind clinical evidence across diverse conditions and populations at unprecedented affordability, speed and scale, a transformative approach that can finally close the proof gap between non-prescription wellness products and pharmaceutical drugs. For the first time in history, any supplement company can now develop innovative and effective products, market strong defensible claims and gain the confidence of all stakeholders—from consumers to healthcare providers to retailers—based on clinical proof.
The Radicle Proof Engine™ delivers on the vision of the Proof-as-a-Service category and establishes a new paradigm.
The Historical Problem: Lack of Clinical Proof
Most natural health products and dietary supplements do not have clinical proof of their effectiveness—a proof gap that leads to significant opportunity loss for the industry and consumers, alike. Unlike patented pharmaceutical drugs, unpatentable supplements cannot afford the multi-million-dollar, multi-year process of traditional clinical trials. This has led to the paradoxical situation where Americans spend 10x more on pharmaceuticals (~$500B/year) than supplements (~$50B/year), even though more Americans take supplements than pharmaceuticals. Fully 80% of Americans use dietary supplements, while 66% of Americans take prescriptions.
Additionally, traditional clinical trials are fundamentally flawed because their trial populations often do not represent the diversity of the broader population. Traditional trials have historically studied mostly Caucasian males living in urban cities, which means the findings do not apply to much of the population at large.